Clinical trial diversity requirements
Everything filed under system in our medical research coverage, the 40 reports filed on it so far.
Bristol Myers' admilparant shows dose-dependent efficacy in IPF trial
Bristol Myers Squibb's Phase 3 trial of admilparant for idiopathic pulmonary fibrosis met its primary endpoint only at the lower 60 mg dose, raising...
BioNTech's BNT113 Fails Key Goal in Head and Neck Cancer Trial
BioNTech's mRNA cancer therapy BNT113 combined with Keytruda did not improve progression-free survival in a Phase 3 trial for HPV-driven head and...
ArriVent's furmonertinib fails key lung cancer trial endpoint
ArriVent BioPharma's oral lung cancer drug furmonertinib failed to significantly delay tumor progression versus chemotherapy in a late-stage study...
Amgen's Sjögren's drug succeeds in first Phase 3 trial
Amgen's experimental drug dazodalibep met its primary goal in a Phase 3 study for Sjögren's syndrome, showing early and sustained symptom improvement.
Remote-Controlled Artificial Sphincter Enters U.S. Trial
An investigational, remote-controlled artificial urinary sphincter is being tested in a 140-patient U.S. and French study for men with incontinence...
EVOKE-03 Trial: Sacituzumab Fails to Boost Survival
The phase III EVOKE-03 trial found adding sacituzumab govitecan to pembrolizumab did not significantly improve survival in untreated metastatic...
Cullinan and Taiho drug extends lung cancer progression-free survival
In a phase 3 trial, adding zipalertinib to chemotherapy improved median progression-free survival to 14.5 months, a six-month gain over chemo alone.
GSK's risvutatug rezetecan shows 18.5-month median overall survival
GSK and Hansoh Pharma's antibody-drug conjugate risvutatug rezetecan achieved a median overall survival of 18.5 months in a phase 3 trial for...
Roivant's lung hypertension drug hits Phase 2 goals
Roivant's mosliciguat reduced a key lung pressure measure by 56% in a Phase 2 trial for PH-ILD, with analysts citing multi-billion dollar potential.
Ketamine Outperforms Midazolam in Bipolar Depression Trial
A small trial found adjunctive ketamine was more effective than midazolam for treatment-resistant bipolar depression.
Novartis Phase 3 Trial Fails for Lp(a) Drug Pelacarsen
Novartis's pelacarsen, an antisense drug developed with Ionis to lower lipoprotein(a), did not reduce major cardiovascular events in high-risk...
ADARx files for IPO to fund three clinical-stage siRNA medicines
ADARx Pharmaceuticals has filed for an initial public offering to raise funds for advancing its pipeline of siRNA therapies.
AI Tool Prof. Valmed Speeds Up Rheumatology Diagnosis
A randomized trial found the AI system Prof. Valmed cut diagnosis time by more than half compared to physicians working alone.
Novartis, Ionis heart drug fails in major Phase 3 trial
Novartis and Ionis Pharmaceuticals' experimental drug pelacarsen failed to reduce heart attacks, strokes or death in a Phase 3 study of over 8,000...
AbbVie's dual-acting myeloma drug etentamig meets Phase 3 endpoint
AbbVie reported that its bispecific antibody etentamig met the primary endpoint in a Phase 3 trial for multiple myeloma.
Extended ECG Monitoring Boosts Arrhythmia Detection
The ASPIRED trial found that immediate 14-day cardiac monitoring for emergency department patients with unexplained fainting doubled arrhythmia...
Novartis, BMS Pause CAR-T Autoimmune Trials
Novartis and Bristol Myers Squibb have paused clinical trials of their CAR T-cell therapies for autoimmune diseases following severe adverse events.
Natera partners with Angiex on cancer trial
Natera has partnered with Angiex to evaluate its Signatera blood test in a phase 1 trial of the cancer drug AGX101.
mRNA cancer vaccine trial succeeds
A personalized mRNA vaccine for melanoma from Moderna and Merck has shown clinical success.
Alnylam defends silencer drugs after AstraZeneca trial failure
Alnylam defends its RNAi drugs after AstraZeneca's heart disease trial failure, arguing they work even for patients on stabilizer therapies.
Transcatheter Tricuspid Repair Cuts Death
The TRIC-I-HF trial shows transcatheter tricuspid valve repair significantly reduces all-cause death and heart failure hospitalization in high-risk...
Syneos Health: Include China Early in Global Clinical Development
Syneos Health advises biotechs to integrate China into global clinical development from the outset.
AstraZeneca, Amgen's Tezspire succeeds in Phase 3 eosinophilic esophagitis trial
AstraZeneca and Amgen's Tezspire succeeded in a Phase 3 trial for eosinophilic esophagitis, potentially expanding the label for the immunology drug.
CMS Rule Tightens Medicaid Work Exemptions
A pulmonologist argues that a new CMS rule on Medicaid work requirements will increase paperwork burdens for clinicians and threaten coverage for...